Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
Date:7/2/2012

lar study conducted by Celator in newly diagnosed elderly patients with secondary AML supported the initiation of the current Phase 3 program. LLS's TAP supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers. 

"This is not only welcome funding but also an important vote of confidence in the potential of CPX-351 to improve outcomes for patients with AML from an organization devoted to that goal," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "Our new agreement extends what has already been a very productive collaboration and we look forward to the day when these efforts  culminate in making a much-needed new treatment option available to patients with AML at large."

About CPX-351
CPX-351 represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the FDA for the treatment of AML. CPX-351 is in late-stage clinical development for the treatment of AML. Celator has completed a successful randomized, phase 2 study comparing CPX-351 to the standard "7+3" regimen of cytarabine:daunorubicin in patients 60 years of age up to and including 75 years of age with newly diagnosed AML and has also completed a randomized, phase 2 study of CPX-351 versus intensive salvage therapy in patients 18 years of age up to and including 65 years of age with AML in first relapse. The second study was supported by the original LLS TAP funding.

About Acute Myeloid Leukemia (AML)
The LLS defines AML as a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow.  According to LLS, in 2012 approximately 12,950 ne
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
2. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. Need for Reduced Healthcare Outlays Creates Strong Growth Potential for Medical Imaging Services, Says Frost & Sullivan
8. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
9. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
10. LHA Life Sciences & Medical Technologies Virtual Conference
11. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  TRACE International today released its ... that prosecutions against individuals and government or business entities ... GER 2012 is the third in an ... trends. "Although the number of outbound enforcement ... remained a priority," said Alexandra Wrage ...
(Date:5/20/2013)... NEW YORK , May 20, 2013  Echo ... Rule 2.5 of the Irish Takeover Rules (the "Announcement"), ... Corporation, plc (NYSE: ELN ) to $12.50 ... financed, cash confirmed and not conditional on due diligence.  ... eliminated.  Royalty Pharma has reserved the right to waive ...
(Date:5/20/2013)... , May 20, 2013 A medical ... use both in space and on Earth was inducted ... The technology assures high quality, secure handling ... low-power ultrasound units, like those used in hospitals and ... the diagnostic imaging solution of choice for human space ...
Breaking Medicine Technology:TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3
... July 27, 2011 HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) ... six months ended June 30, 2011, after the close of ... A conference call with management is scheduled for 5:00 ... (being 7:00 am Australian Eastern Standard Time, Friday, August 5, ...
... July 27, 2011 Stryker Neurovascular, a division of ... and Platinum Science (MAPS) Trial during the Society of ... The MAPS Trial establishes a new standard for the ... (TAR)*, and proves that coiling is an excellent treatment ...
Cached Medicine Technology:HeartWare to Report Financial Results for Second Quarter of 2011 2Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms 2Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms 3
(Date:5/20/2013)... 20, 2013 Gilman Law LLP, a ... investigating Byetta lawsuits, is troubled by a new study ... and similar type 2 diabetes drugs are growing. ... Practices (ISMP), found that 71 Byetta pancreatic cancer reports ... Administration (FDA) as of June 30, 2012. ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Headquartered in ... Levy Phillips & Konigsberg LLP (“LPK”) has ... White Plains, New York. LPK will better serve people ... Hudson Valley, including Westchester, Putnam, Rockland, Orange, and Dutchess ... affected by asbestos-related diseases throughout New York, New Jersey, ...
(Date:5/20/2013)... Online education provides the convenience, ... does not offer. According to the American Heart ... switching classroom learning to eLearning due to changing ... helped maximize training budgets, but it is also ... by 25–60%. A higher retention of content is ...
(Date:5/20/2013)... comprised over 24,000 Finnish subjects and was led ... a panel of 28 genetic markers improved detection ... disease (CHD) (10-year risk ≥20%) over traditional risk ... important preventive strategy for CHD, because the current ... "The results indicate that genetic markers could be ...
(Date:5/20/2013)... when a particular strain of avian influenza might become ... to be published in the International Journal Data ... University of Arizona, Tucson, and colleagues at the Huazhong ... Institute of Virology, explain that since 1997 several strains ... "bird flu" have infected people directly from their natural ...
Breaking Medicine News(10 mins):Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Predicting infectious influenza 2
... TV Ad Rebrands California Republican Party as the ,Yacht Party, for ... Supporting ,Yacht Tax, ... Courage Campaign have released a new ad branding the California,Republican Party ... that allows buyers of yachts and private jets to avoid paying,sales ...
... sellout for Actifirm(R), a,leading manufacturer of science-based skin ... on QVC Saturday, May 10., QVC program ... six Actifirm products, including 10% Z-Peel(R); Face Firm(TM);,Renovation ... discovery kit with Actifirm products for cleansing, exfoliating,and ...
... CMS Regulatory Action a,Serious Public Policy Misstep; Seniors, Nursing ... OH, IL, PA, NJ, MI, MA, WASHINGTON, May ... the Bush Administration,s $770 million cut to,Medicare-financed nursing home ... regulatory-driven cuts not only jeopardize seniors,access to quality nursing ...
... children exposed to tobacco smoke respond particularly well ... Jewish Medical and Research Center. Associate Professor ... also identified two biomarkers that may help physicians ... from montelukast. , These findings will help doctors ...
... - Significant Increase by 31,6% in Sales and 10,3 % in Net ... 31,6% of the Consolidated Sales to EUR 11,3m in the First ... - Increased by 12,7% of the Consolidated EBITDA to EUR 2,6m (from ... Net Profits (EAT) Increased by 10,3% to EUR 1,5m (from EUR 1,4m in ...
... Pepper Award nominations, DETROIT, May 13 ... lives of Michigan,s senior citizens have until June ... Shield of Michigan,s Claude,Pepper Award., The award ... volunteer efforts have made significant contributions to improving ...
Cached Medicine News:Health News:California Nurses Association, Courage Campaign, Arianna Huffington Team up for 'Yacht Party 2' TV Ad 2Health News:California Nurses Association, Courage Campaign, Arianna Huffington Team up for 'Yacht Party 2' TV Ad 3Health News:Actifirm Sells Out in First Hour Appearance on QVC 2Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 2Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 3Health News:New Studies of Bush Administration $770 Million SNF Medicare Cut Find Seniors' Care Jeopardized, Local Jobs Lost, National and State Economies Threatened 4Health News:Girls and children exposed to tobacco smoke benefit more from montelukast (singulair) 2Health News:KORRES Q1 2008 Results 2Health News:Blue Cross Blue Shield of Michigan Seeking Nominations for Outstanding Senior Advocates 2
... TM-1 is a compact multi-functional ... precise measurement of UVA, UVB, ... all types of lens materials. ... connect with a personal computer ...
... This sleek, contoured instrument table ... room dcor, while providing a sturdy, ... wheelchair compatible design provides completely open ... make positioning quick and easy. The ...
If youre looking to expand your projection capabilities, without a major capital investment, consider Topcons CP-5D Chart Projector....
... corrected curve trial lenses are ground with the ... refractors and are invaluable in treating low vision ... manufacturers contain a disproportionately large number of lenses ... to produce, and fewer lenses in the higher ...
Medicine Products: